Section Arrow
Quote
MDXG.NASDAQ
- MiMedx Group
Quotes are at least 15-min delayed:2026/04/21 22:31 EDT
Regular Hours
Last
 3.2
-0.05 (-1.54%)
Day High 
3.375 
Prev. Close
3.25 
1-M High
4.315 
Volume 
1.98M 
Bid
3.2
Ask
3.29
Day Low
3.185 
Open
3.26 
1-M Low
3.2 
Market Cap 
482.84M 
Currency 美元 
P/E 10.53 
%Yield -- 
10-SMA 3.75 
20-SMA 3.87 
50-SMA 4.44 
52-W High 7.99 
52-W Low 3.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.32/0.79
Enterprise Value
499.31M
Balance Sheet
Book Value Per Share
1.73
Cash Flow
Cash Flow Yield
0.15
Income Statement
Total Revenue
418.63M
Operating Revenue Per Share
2.08
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
GERNGeron Corp1.5-0.06-3.85%-- 
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.